228 related articles for article (PubMed ID: 22538464)
1. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.
Tobinai K; Takahashi T; Akinaga S
Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464
[TBL] [Abstract][Full Text] [Related]
2. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
3. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
4. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT; Lewis DJ; Duvic M
Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
[TBL] [Abstract][Full Text] [Related]
7. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
Remer M; Al-Shamkhani A; Glennie M; Johnson P
Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
[TBL] [Abstract][Full Text] [Related]
8. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
[TBL] [Abstract][Full Text] [Related]
9. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
10. Antibody therapy for Adult T-cell leukemia-lymphoma.
Ishida T; Ueda R
Int J Hematol; 2011 Nov; 94(5):443-52. PubMed ID: 21993874
[TBL] [Abstract][Full Text] [Related]
11. CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.
Sakamoto Y; Fujii K; Murase S; Nakano S; Masaki A; Murase T; Kusumoto S; Iida S; Utsunomiya A; Ueda R; Ishida T; Inagaki H
Int J Hematol; 2019 Oct; 110(4):389-392. PubMed ID: 31468320
[TBL] [Abstract][Full Text] [Related]
12. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
de Lartigue J
Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
[TBL] [Abstract][Full Text] [Related]
13. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma.
Fujii K; Sakamoto Y; Masaki A; Murase T; Tashiro Y; Yonekura K; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Ishida T; Inagaki H
J Pathol Clin Res; 2021 Jan; 7(1):52-60. PubMed ID: 33022137
[TBL] [Abstract][Full Text] [Related]
15. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.
Ishida T; Utsunomiya A; Jo T; Yamamoto K; Kato K; Yoshida S; Takemoto S; Suzushima H; Kobayashi Y; Imaizumi Y; Yoshimura K; Kawamura K; Takahashi T; Tobinai K; Ueda R
Cancer Sci; 2017 Oct; 108(10):2022-2029. PubMed ID: 28776876
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
[TBL] [Abstract][Full Text] [Related]
17. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
Ishida T; Joh T; Uike N; Yamamoto K; Utsunomiya A; Yoshida S; Saburi Y; Miyamoto T; Takemoto S; Suzushima H; Tsukasaki K; Nosaka K; Fujiwara H; Ishitsuka K; Inagaki H; Ogura M; Akinaga S; Tomonaga M; Tobinai K; Ueda R
J Clin Oncol; 2012 Mar; 30(8):837-42. PubMed ID: 22312108
[TBL] [Abstract][Full Text] [Related]
18. Persistent complete remission of acute leukemic-phase CCR4-positive gamma-delta peripheral T-cell lymphoma by autologous stem cell transplantation with mogamulizumab.
Furukawa M; Ikeda K; Ohkawara H; Saito S; Takahashi H; Ueda K; Matsumoto H; Hashimoto Y; Ohto H; Ogawa K; Takeishi Y
Int J Hematol; 2015 Oct; 102(4):498-505. PubMed ID: 25975265
[TBL] [Abstract][Full Text] [Related]
19. Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo.
Shimizu Y; Koyasu S; Suzukida M; Izumi K; Kidera E; Shindo T; Saga T; Ono M; Takaori-Kondo A; Nakamoto Y
Ann Nucl Med; 2022 Mar; 36(3):319-326. PubMed ID: 35034259
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the treatment of adult T-cell leukemia-lymphomas.
Utsunomiya A; Choi I; Chihara D; Seto M
Cancer Sci; 2015 Apr; 106(4):344-51. PubMed ID: 25613789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
